News and Press Releases
Takeda Type 2 Diabetes Therapies, NESINA (alogliptin) and Fixed-Dose Combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone), Are Now Available in Pharmacies in the United States
Takeda and Sea Lane Biotechnologies Sign Licensing Agreement For Use of ConCIRT Libraries and Technology
Takeda to Acquire Envoy Therapeutics, Inc.
Closure of Takeda California San Francisco Site and Relocation of Takeda Antibody and Biologics Research to San Diego
Takeda California Mobilizes to Support Healthy Living and Combat Diabetes
Takeda to Acquire Intellikine, Adding Two Novel Programs to its Oncology Pipeline
Approval of Additional Indications of “NESINA®”: Combination Therapy with Sulfonylurea and Combination Therapy with Biguanide for Type 2 Diabetes in Japan
President & CSO of Takeda San Francisco chairs the session about Expanding Research Capabilities through Global Partnerships: The New Symbiotic Relationship at 16th Annual BioPartnering Europe October 12-14, 2008 in London, UK
Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
Takeda Established a New Company in the U.s. for Therapeutic Antibody Research
Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
XOMA and Takeda Establish Collaboration for Therapeutic Antibody Discovery and Development